Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America”(Journal of Cardiac Failure (2019) 25(8) (584–619), (S1071916419305214), (10.1016/j.cardfail.2019.05.007))

THEAMERICAN HEART ASSOCIATION HEART FAILURE AND TRANSPLANTATION COMMITTEE OF THE COUNCIL ON CLINICAL CARDIOLOGYCOUNCIL ON CARDIOVASCULAR AND STROKE NURSINGHEART FAILURE SOCIETY OF AMERICA

Research output: Contribution to journalComment/debate

Abstract

In the above article a correction is needed. On page 601, left hand column, in the “Use of Glucose-Lowering Medications With CKD” section, first paragraph, the last sentence read, “Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CANVAS [just stopped prematurely for efficacy]…” It should have read,” Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CREDENCE [just stopped prematurely for efficacy]…”

Original languageEnglish (US)
JournalJournal of Cardiac Failure
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Type 2 Diabetes Mellitus
Heart Failure
Hand
Glucose
corrigendum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America”(Journal of Cardiac Failure (2019) 25(8) (584–619), (S1071916419305214), (10.1016/j.cardfail.2019.05.007)). / THEAMERICAN HEART ASSOCIATION HEART FAILURE AND TRANSPLANTATION COMMITTEE OF THE COUNCIL ON CLINICAL CARDIOLOGYCOUNCIL ON CARDIOVASCULAR AND STROKE NURSINGHEART FAILURE SOCIETY OF AMERICA.

In: Journal of Cardiac Failure, 01.01.2019.

Research output: Contribution to journalComment/debate

THEAMERICAN HEART ASSOCIATION HEART FAILURE AND TRANSPLANTATION COMMITTEE OF THE COUNCIL ON CLINICAL CARDIOLOGYCOUNCIL ON CARDIOVASCULAR AND STROKE NURSINGHEART FAILURE SOCIETY OF AMERICA. / Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America”(Journal of Cardiac Failure (2019) 25(8) (584–619), (S1071916419305214), (10.1016/j.cardfail.2019.05.007)). In: Journal of Cardiac Failure. 2019.
@article{d584f3a633e4471c878d154fc489890f,
title = "Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America”(Journal of Cardiac Failure (2019) 25(8) (584–619), (S1071916419305214), (10.1016/j.cardfail.2019.05.007))",
abstract = "In the above article a correction is needed. On page 601, left hand column, in the “Use of Glucose-Lowering Medications With CKD” section, first paragraph, the last sentence read, “Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CANVAS [just stopped prematurely for efficacy]…” It should have read,” Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CREDENCE [just stopped prematurely for efficacy]…”",
author = "{THEAMERICAN HEART ASSOCIATION HEART FAILURE AND TRANSPLANTATION COMMITTEE OF THE COUNCIL ON CLINICAL CARDIOLOGYCOUNCIL ON CARDIOVASCULAR AND STROKE NURSINGHEART FAILURE SOCIETY OF AMERICA} and Dunlay, {Shannon M} and GIVERTZ, {MICHAEL M.} and DAVID AGUILAR and ALLEN, {LARRY A.} and MICHAEL CHAN and DESAI, {AKSHAY S.} and ANITA DESWAL and DICKSON, {VICTORIA VAUGHAN} and KOSIBOROD, {MIKHAIL N.} and LEKAVICH, {CAROLYN L.} and Rozalina McCoy and MENTZ, {ROBERT J.} and PINA, {ILEANA L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cardfail.2019.08.006",
language = "English (US)",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America”(Journal of Cardiac Failure (2019) 25(8) (584–619), (S1071916419305214), (10.1016/j.cardfail.2019.05.007))

AU - THEAMERICAN HEART ASSOCIATION HEART FAILURE AND TRANSPLANTATION COMMITTEE OF THE COUNCIL ON CLINICAL CARDIOLOGYCOUNCIL ON CARDIOVASCULAR AND STROKE NURSINGHEART FAILURE SOCIETY OF AMERICA

AU - Dunlay, Shannon M

AU - GIVERTZ, MICHAEL M.

AU - AGUILAR, DAVID

AU - ALLEN, LARRY A.

AU - CHAN, MICHAEL

AU - DESAI, AKSHAY S.

AU - DESWAL, ANITA

AU - DICKSON, VICTORIA VAUGHAN

AU - KOSIBOROD, MIKHAIL N.

AU - LEKAVICH, CAROLYN L.

AU - McCoy, Rozalina

AU - MENTZ, ROBERT J.

AU - PINA, ILEANA L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the above article a correction is needed. On page 601, left hand column, in the “Use of Glucose-Lowering Medications With CKD” section, first paragraph, the last sentence read, “Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CANVAS [just stopped prematurely for efficacy]…” It should have read,” Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CREDENCE [just stopped prematurely for efficacy]…”

AB - In the above article a correction is needed. On page 601, left hand column, in the “Use of Glucose-Lowering Medications With CKD” section, first paragraph, the last sentence read, “Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CANVAS [just stopped prematurely for efficacy]…” It should have read,” Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CREDENCE [just stopped prematurely for efficacy]…”

UR - http://www.scopus.com/inward/record.url?scp=85070916275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070916275&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2019.08.006

DO - 10.1016/j.cardfail.2019.08.006

M3 - Comment/debate

C2 - 31174952

AN - SCOPUS:85070916275

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

ER -